Pro-Angiogenic Effects of Chalcone Derivatives in Zebrafish Embryos in Vivo

Yau-Hung Chen 1,*, Chao-Yuan Chang 1, Chiung-Fang Chang 2, Po-Chih Chen 3, Ya-Ting Lee 1, Ching-Yuh Chern 3,* and Jen-Ning Tsai 4,5,*

1 Department of Chemistry, Tamkang University, 151, Ying-chuan Road, Danshui District, New Taipei City 25137, Taiwan; E-Mails: frank00634@hotmail.com (C.-Y.C.); joanna20520@gmail.com (Y.-T.L.)
2 Department of Life Sciences, National Chung Hsing University, Taichung 40227, Taiwan; E-Mail: kitomint@hotmail.com
3 Department of Applied Chemistry, National Chia-Yi University, Chia-Yi 60004, Taiwan; E-Mail: tpdyha6606@gmail.com
4 School of Medical Laboratory and Biotechnology, Chung Shan Medical University, Taichung 40201, Taiwan
5 Clinical Laboratory, Chung Shan Medical University Hospital, Taichung 40201, Taiwan

* Authors to whom correspondence should be addressed; E-Mails: yauhung@mail.tku.edu.tw (Y.-H.C.); cychern@mail.ncyu.edu.tw (C.-Y.C.); jeningts@csmu.edu.tw (J.-N.T.); Tel.: +886-2-2621-5656 (ext. 3009) (Y.-H.C.); Fax: +886-2-2620-9924 (Y.-H.C.).

Academic Editor: Derek J. McPhee

Received: 20 April 2015 / Accepted: 6 July 2015 / Published: 9 July 2015

Abstract: The aim of this study was to investigate novel chalcones with potent angiogenic activities in vivo. Chalcone-based derivatives were evaluated using a transgenic zebrafish line with fluorescent vessels to real-time monitor the effect on angiogenesis. Results showed that the chalcone analogues did not possess anti-angiogenic effect on zebrafish vasculatures; instead, some of them displayed potent pro-angiogenic effects on the formation of the sub-intestinal vein. Similar pro-angiogenic effects can also be seen on wild type zebrafish embryos. Moreover, the expression of vegfa, the major regulator for angiogenesis, was also upregulated in their treatment. Taken together, we have synthesized and identified a series of novel chalcone-based derivatives as potent in vivo pro-angiogenic compounds. These novel compounds hold potential for therapeutic angiogenesis.
Keywords: angiogenesis; chalcones; in vivo; zebrafish embryos

1. Introduction

Chalcone (1,3-diphenyl-2-propen-1-one), abundant in edible plants, is essential for the biosynthesis of flavonoids and isoflavonoids [1]. Natural occurring chalcones and chalcone-based derivatives have been demonstrated to possess diverse pharmacological activities, such as anti-oxidant, anti-inflammatory, anti-bacterial, and anti-tumor activity [2–7]. A recent study indicated that one of the mechanisms for anti-tumor activity is to inhibit angiogenesis [8].

Angiogenesis, the formation of new blood vessels from pre-existing vessels, is required for various physiological processes, such as development, growth and wound healing [9]. Angiogenesis occurs during embryonic development, and continues into adult life. Many human diseases arise from inadequate changes in tissue vascularization and oxygen availability [10]. For example, insufficient vascular growth contributes to coronary artery disease, while excess angiogenesis promotes growth and metastasis of tumor. Therefore molecules possessing pro- or anti-angiogenic effect hold great potential for treating diseases. During normal physiological condition, the balance between pro- and anti-angiogenic factors is essential for regulating angiogenesis [11]. VEGF and its tyrosine kinase receptors (VEGFRs) are the key regulators in angiogenesis and are highly conserved across vertebrate species [12]. Among them, VEGF-A, the most important member of VEGF, binds and activates the VEGFR2 (KDR), subsequently activate the main signaling pathway [13].

Many in vitro and in vivo models have been used for analyzing angiogenesis. These include the endothelial cell line derived from human umbilical cord vein or from organ specific endothelial cells. Many in vivo models, such as chick embryo, rabbit and mouse, have also been developed for analyzing angiogenesis [14]. However, large-scale chemical screening with these models has been hampered due to the cost and space needed for breeding. Zebrafish (Danio rerio) is a useful tool for analyzing developmental processes and modeling human genetic diseases [15]. Zebrafish possess a closed circulatory system, and the molecular mechanisms underlying its vascular development are highly similar to those of higher vertebrates [16]. Compared with other animal models, zebrafish offers several advantages in studying vascular development. For example, their embryos are transparent during early development and they can survive through the first week with no blood circulation. Finally, the generation of the transgenic zebrafish fish line with fluorescent vessels, such as Tg(fli1:egfp) [17], allows real-time observation of vascular growth in vivo. These features have made zebrafish a powerful animal model in large-scale chemical screening for pro- or anti-angiogenic molecules.

The present study aimed to investigate the angiogenic effects of novel chalcone-based derivatives in zebrafish in vivo model. Several chalcones were found to possess pro-angiogenic effect in wild type and transgenic line Tg(fli1:egfp) as evidenced by induction of ectopic subintestinal vein (SIV). Further investigation revealed that the expression of vegfa, an important angiogenic regulator, was upregulated on the treatment of these pro-angiogenic chalcone-based derivatives.
2. Results and Discussion

2.1. Chemistry

For this study, we synthesized five chalcones 1a, 1b, 1c, 1d and 1e (Figure 1A). Since it is possible that intramolecular hydrogen bonds observed in 1a–e prevents aldol reactions, these aldol intermediates were obtained by using the similar procedure described previously [4,18–20]. Therefore, O-isoproxyacetophenones 3a–e and O-isoproxybenzaldehydes 6a–c were used as the starting material for our synthesis. The preparations of O-isoproxyacetophenones 3a–e and O-isoproxybenzaldehydes 6a–c were straightforward. Acetophenones 2a–e and benzaldehydes 5a–c were protected in excellent yield with isopropyl bromide and potassium carbonate in DMF. The isolated products 3a–e were then reacted with appropriate benzaldehydes 6a–c and 5N KOH to provide intermediates 4a–e in 64%, 70%, 75%, 81% and 74% yields, respectively. The O-isopropyl ether was removed quantitatively with BCl3 to afford the target chalcones 1a–e (Figure 1B), and each compound displayed >95% purity based on the 1H-NMR results. We were the first group to develop the methodology and protocols [4] to synthesize the target compounds 1a–e. The intermediate compounds 2b–d, 3b–d, and 4b–d reported in the present study are new and have not been reported before. Since we have previously reported the synthesis of 1a and 1e, the intermediate products (2a, 2e, 3a, 3e, 4a, and 4e) are not considered to be new. In the present study, we employed the same methodology to synthesize the new compound 1b, 1c, and 1d.

![Figure 1](image_url). Structures and synthesis of chalcone and its derivatives. (A) Structures of chalcone and compound 1a–e; (B) Synthesis of compounds 1a–e.
2.2. Chalcones Induced Pro-Angiogenic Effect on Zebrafish Embryos

During zebrafish embryonic development, angiogenesis is best characterized by formation of intersegmental vessels (ISV) and subintestinal veins (SIV). In zebrafish embryos, vascular development initiates at around 12 hour-post-fertilization (hpf), when hemangioblasts first appear along the lateral plate mesoderm. At 24 hpf, two axial vessels, the dorsal aorta (DA) and posterior cardinal vein (PCV), are first formed in the trunk of embryos. Meanwhile, bilateral ISVs sprout dorsally from the DA and finally reach the dorsal-most region of the somites and split dorsolaterally to form the dorsal longitudinal anastomotic vessels (DLAVs). The SIVs, originating from the common cardinal vein (duct of Cuvier) at 48 hpf, form in the shape of a basket on the dorsolateral surface of the yolk at 3 dpf [21]. In the presence of anti-angiogenic signal, defective ISV can be easily observed as judged by the shortened or no ISV formation. However, in the presence of pro-angiogenic stimulus, increased angiogenesis is not easily detected in ISV. Aberrant angiogenic sprouting appears until 3.5 dpf and can only be detected unambiguously by confocal microscopy [22]. On the contrary, observation of SIV development is suitable for detecting either anti- or pro-angiogenic compounds by simply calculating the number or length of SIV [23]. Additionally, SIV development can also be easily monitored in wild type embryos by the staining endogenous alkaline phosphatase activity, which is not present in early developing ISV.

To examine the effect of chalcones on vascular development of zebrafish embryos, we first treated the transgenic Tg(fli1:egfp) embryos with chalcones via two exposure methods to examine the effect on ISV (method I, 12–36 hpf) or SIV development (method II, 12–72 hpf) (Figure 2). Treatment of chalcones with 1 or 3 ppm via exposure method I caused no significant change in the formation of ISVs (Figure 3 and data not shown), suggesting that chalcone derivatives had no effect on the initial development of trunk vasculature in zebrafish embryos.

Figure 2. Exposure methods used in this study. Zebrafish wild type or Tg(fli1:egfp) embryos were treated with different concentration of chemicals from 12 to 36 hpf (method I) or from 12 to 72 hpf (method II). The embryos treated via method I were subjected to the analysis of intersegmental vessels (ISVs) formation, while those treated via method II were subjected to analysis of subintestinal veins (SIVs) formation.
Figure 3. Chalcone derivatives had no effect on the formation of angiogenic intersegmental vessels (ISVs). (A–D) Representative images of zebrafish trunk ISVs treated with 3 ppm of chalcone and its derivatives (in 0.12% DMSO) via exposure method I. All figures are lateral views with dorsal to the top and anterior to the left. The fluorescent vessels of embryos were observed at 36 hpf. Vehicle: 0.12% DMSO only.

However, when transgenic zebrafish embryos were treated with chalcones via method II, some derivatives (compounds 1a, 1c and 1e) induced abnormal patterning of the SIVs as evidenced by the additional branches of SIVs and the ectopic sprouting vessels outside the SIV basket (Figure 4A–D), suggesting that some chalcone compounds had pro-angiogenic activity on zebrafish embryos. Compound 1b had no pro-angiogenic activity, whereas compound 1d (1 ppm) was extremely toxic (no survival embryos were observed after compound 1d treatment). The quantification of pro-angiogenic effect on SIVs was measured by counting the SIV numbers in the treated embryos (Figure 4E–H). Chalcones slightly increased the numbers of SIVs at 0.1 ppm when compared to the vehicle control group. When the concentration of chemicals was elevated to 1 ppm, the pro-angiogenic effect was more pronounced as evidenced by the 1.5–2.3 fold of increase in the numbers of SIVs. The result indicated that chalcone derivatives (compounds 1a, 1c and 1e) induce neovascularization in zebrafish SIVs in a dose-dependent manner. Among them, compounds 1c and 1e were more potent than the other derivatives in inducing ectopic SIV vessels (Figure 4I). As 2′-hydroxy-4-methoxychalcone (HMC) had been reported to possess anti-angiogenic activity using cell culture and chicken chorioallantoic membrane assay [24], we next explored whether this chalcone derivative had similar effect in the zebrafish embryos. Treatment of HMC at 3 ppm via method II resulted in anti-angiogenic effect in zebrafish embryos as evidenced by the decreased numbers of SIVs compared with vehicle control (Figure 4I). The above result indicated that zebrafish SIVs as a reliable model system for angiogenic study.
Figure 4. Chalcone derivatives caused pro-angiogenic effect on the zebrafish transgenic line Tg(fli1:egfp). (A–D) Representative images of fluorescent SIV basket of embryos treated with water containing 0.12% DMSO (vehicle) or chalcones derivatives (in 0.12% DMSO) via exposure method II. The fluorescent vessels of embryos were observed at 72 hpf; (E–H) Enlarged SIV regions in (A–E). The number of SIV was defined as the sum of the number of vessel within the SIV plus the number of angiogenic outgrowth sprouts (marked by asters); (I) Data are the mean ± S.D. of twenty embryos from three independent experiments (n = 60 in each group). A t-test with 0.05 of significance level, carried out by JMP statistical software (version 4.02), was used to assess the difference in the number of SIV between two groups. The result reported the number of SIV for all experiment groups are significantly different from vehicle group (*: p < 0.0001).

To demonstrate whether the pro-angiogenic effect of chalcones can also be observed in wild type embryos, we treated the chemicals with wild type embryos via method II and visualized the SIV formation by endogenous alkaline phosphatase staining. GS4012, a pro-angiogenic compound, and HMC, the chalcone with anti-angiogenic activity, were included as positive and negative controls in the assay,
respectively. As expected, GS4012 treatment led to increased numbers of SIV than vehicle group, whereas HCM treatment caused decreased numbers of SIV (Figure 5A–C). Similar to what was observed in transgenic Tg(fli1:egfp) embryos, increased numbers of the branch and ectopic SIV sprouting were also detected in chalcones-treated embryos when compared with vehicle control groups (Figure 5E–H). In addition, observation in wild type and Tg(fli1:egfp) transgenic embryos both showed that chalcone 1c and 1e exerts greater potent pro-angiogenic effects than 1a. Taken together, chalcone derivatives had similar pro-angiogenic effect on both wild type and the transgenic embryos with fluorescent vessels.

![Figure 5](image)

**Figure 5.** Chalcone derivatives caused pro-angiogenic effect on the wild type zebrafish. (A–F) Representative images of AP-stained SIV basket of embryos treated with GS4012, HMC, and chalcone derivatives via exposure method II; (G–L) Enlarged SIV regions in (A–F). The number of SIV was defined as the sum of the number of vessel within the SIV plus the number of angiogenic outgrowth sprouts (marked by asters). Embryos at 72 hpf were subjected to alkaline phosphatase staining.

### 2.3. Molecular Mechanism of Pro-Angiogenic Effects of Chalcone-Based Derivatives

To further explore the molecular mechanism of pro-angiogenic effects, we next investigated the effects of chalcone derivatives on the expression of *vegfa*, the major ligand in VEGF signaling. In zebrafish, the *vegfa* gene is duplicated and the two genes are named *vegfaa* and *vegfab* [25]. Zebrafish *vegfaa* can produce two different isoforms: a 121-amino acid isoform (*vegfaa*121) and a 165-amino acid protein (*vegfaa*165). Previous studies showed that *vegfaa*121 is mainly involved in the formation of ISVs [26,27], whereas the *vegfaa*165 is primarily implicated in the formation of SIVs [27]. Due to the pro-angiogenic effect of SIVs on the treatment of chalcone-based derivatives, we investigated the expression of *vegfaa*165 using embryos treated with either compound 1a, 1c or 1e through method I (12–36 hpf). By performing whole-mount *in situ* hybridization, we found that the mRNA levels of *vegfaa*165 in the chalcones-treated embryos were all upregulated as compared with the control groups (Figure 6). The expression of *vegfaa*165...
was strongly enhanced in the anterior parts of embryos and moderately increased in adjacent somite areas along the trunk vascular regions (compare Figure 6B–D with 6A). Therefore, we speculated that the VEGF pathway might play a role in the pro-angiogenic effect of chalcone-based derivatives.

**Figure 6.** Effects of chalcone derivatives on the expression of *vegfaa*165. Whole-mount *in situ* hybridization was utilized to analyze the expression of *vegfaa*165 in zebrafish embryos treated with DMSO vehicle (A); 3 ppm of compound 1a (B); 1c (C) or 1e (D) via exposure method I. Embryos at 36 hpf were subjected to whole-mount *in situ* hybridization. All figures were lateral views with anterior to the left and dorsal at the top.

Cardiovascular and cerebrovascular diseases remain the main causes of death worldwide. These diseases are often associated with blockade or narrowing of the blood vessel network in the affected tissues or organs. Restoring blood supply in the affected regions is essential in the successful treatment of these ischemic diseases. Thus, compounds possessing pro-angiogenic activity are clinically important in therapeutic angiogenesis. Many natural and synthetic chalcone-based derivatives had been found to possess anti-angiogenic activities [8,22,28,29]. In the present study, we synthesized a series of novel chalcone-based derivatives and evaluated their angiogenic effect by zebrafish *in vivo* model. While the syntheses of compound 1a and 1e had been described in our previous report [4], the syntheses of 1b, 1c, and 1d were first reported in the present study. Among them, chalcone derivatives, including compounds 1a, 1c and 1e was found to induce ectopic SIV. The induction of ectopic blood vessels was accompanied by the enhanced expression of a key regulator of angiogenesis, *vegfa*. The exact mechanism of chalcone-based derivatives on the induction of *vegfa* expression is currently under investigation.
3. Experimental Section

3.1. Synthesis Chalcone Analogue

Melting points of the synthesized compounds were determined in open capillary tubes and are uncorrected. Proton NMR spectra were recorded at 300 MHz Varian Mercury-300 NMR spectrometer (Agilent, Santa Clara, CA, USA). Carbon NMR spectra were recorded at 75 MHz Varian Mercury-300 NMR spectrometer (Agilent). Proton and carbon chemical shifts are reported on the delta scale as parts per million (ppm) downfield from tetramethylsilane (TMS) as internal reference. Mass spectra were measured with a VG Analytical Model 70–250 s Mass Spectrometer, Varian, Palo Alto, CA, USA. All reagents were used as obtained commercially.

3-(4-Hydroxyphenyl)-1-(2-hydroxyphenyl)-propenone (1a): M.p. 164 °C (lit. [1] 157–158); 1H-NMR (CDCl3): 12.80 (1H, s, –OH), 10.80 (1H, s, –OH), 8.26 (1H, d, J = 8.0 Hz), 7.89 (1H, d, J = 15.6 Hz), 7.77 (1H, d, J = 15.6 Hz), 7.71 (2H, d, J = 8.4 Hz, 7.54 (1H, td, J = 8.1 Hz, 1.0 Hz), 7.01–6.95 (2H, m), 6.86 (2H, d, J = 8.4 Hz); 13C-NMR (CDCl3): 193.8, 163.5, 160.9, 145.4, 136.4, 134.5, 130.9, 125.8, 120.7, 119.3, 118.8, 117.9, 116.2; EI-MS m/z (rel.int.%): 240 (M+,100), 239 (63), 223 (33), 147 (17), 121 (55), 91 (94), 77 (28), 65 (33).

3-(3-Hydroxyphenyl)-1-(4-hydroxyphenyl)-propenone (1b): M.p. 259–260 °C (lit. [2] 261–262); 1H-NMR (d6-acetone): 9.40 (1H, s, –OH), 8 .65 (1H, s, –OH), 8.07 (2H, d, J = 8.8 Hz), 7.77 (1H, d, J = 15.8 Hz), 7.29–7.21 (3H, m), 6.97 (2H, d, J = 8.8 Hz), 7.00–6.83 (1H, m); 13C-NMR (d6-acetone): 188.1, 162.8, 158.7, 143.9, 137.6, 131.9, 131.2, 130.8, 122.9, 120.8, 118.2, 116.2, 115.8; EI-MS m/z (rel.int.%): 240 (M+,100), 239 (63), 223 (33), 147 (17), 121 (55), 91 (16), 65 (29).

3-(2-Hydroxyphenyl)-1-(3-hydroxyphenyl)-propenone (1c): M.p. 173 °C (lit. [3] 173–174); 1H-NMR (d6-acetone): 9.32 (1H, s, –OH), 8.83 (1H, s, –OH), 8.15 (1H, d, J = 15.8 Hz), 7.75 (1H, d, J = 15.8 Hz), 7.62–7.57 (2H, m), 7.43–7.37 (3H, m), 6.10 (1H, d, J = 3.0 Hz), 5.96 (1H, d, J = 3.0 Hz), 3.90 (3H, s), 3.82 (3H, s); 13C-NMR (d6-acetone, 75 MHz): 189.7, 158.0, 157.3, 140.3, 139.8, 131.9, 130.6, 129.3, 122.3, 122.0, 120.2, 120.0, 119.9, 116.5, 115.0; EI-MS m/z (rel.int.%): 240 (M+,72), 239 (100), 223 (91), 147 (45), 121 (23), 91 (27), 65 (22).

1-(2-Hydroxy-4,6-dimethoxyphenyl)-3-phenylpropenone (1d): M.p. 91–92 °C (lit. [4] 85–86); 1H-NMR (d6-acetone): 14.09 (1H, s, –OH), 8.88 (1H, d, J = 15.6 Hz), 7.75 (1H, d, J = 15.6 Hz), 7.62–7.57 (2H, m), 7.43–7.37 (3H, m), 6.10 (1H, d, J = 3.0 Hz), 5.96 (1H, d, J = 3.0 Hz), 3.90 (3H, s), 3.82 (3H, s); 13C-NMR (d6-acetone, 75 MHz): 192.5, 168.3, 166.1, 162.4, 142.2, 135.4, 129.9, 128.8, 128.2, 127.4, 106.2, 93.7, 91.1, 55.7, 55.4; EI-MS m/z (rel.int.%): 284 (M+,84), 283 (65), 207 (100), 181 (34), 103 (16), 77 (13).

1-(2,6-Dihydroxy-4-methoxyphenyl)-3-phenylpropenone (1e): M.p. 145 °C; 1H-NMR (d6-acetone): 12.07 (2H, s, –OH), 8.25 (1H, d, J = 15.6 Hz), 7.79 (1H, d, J = 15.6 Hz), 7.71–7.66 (2H, m), 7.46–7.40 (3H, m), 6.04 (2H, s), 3.81 (3H, s); 13C-NMR (d6-acetone): 193.4, 167.2, 165.4, 142.9, 136.4, 130.9, 129.8, 129.1, 128.3, 106.2, 94.6, 55.8; EI-MS m/z (rel.int.%): 270 (M+,6), 233 (15), 206 (22), 191 (23), 178 (100), 163 (26), 103 (45), 77 (59), 65 (24).
3.2. Fish Care

Mature zebrafish (wild type, WT; AB strain) and Tg(fli1:egfp) [17] were maintained at 28 °C with a photoperiod of 14 h light and 10 h dark, in an aquarium supplied with freshwater and aeration. Embryos were produced using standard procedures [30] and were staged according to standard criteria (hours postfertilization—hpf) or by days postfertilization (dpf) [31].

3.3. Chemical Treatment and Observation of Blood Vessels

Chemicals were treated to zebrafish embryos according to method I (12–36 hpf) or method II (12–72 hpf) described in Figure 2. Chalcone derivatives were dissolved in dimethylsulfoxide (DMSO) as stock solution (2500 ppm), and diluted to 3 ppm for treatment. For vehicle group, the final concentration of DMSO is 0.12%. To facilitate the visualization of blood vessels, phenylthiourea (PTU) was added into the media at a final concentration of 0.003% to inhibit melanization. At 36 or 72 hpf, photos of the ISVs or SIVs of the embryos were taken under a fluorescence microscope (Leica MZ95, Wetzlar, Germany) by a digital camera (Leica DFC 490).

3.4. Endogenous Alkaline Phosphatase Staining

Endogenous alkaline phosphatase activity was performed as described previously [32]. Briefly, the embryos were fixed with 4% paraformaldehyde at 4 °C overnight and permeated by acetone at −20 °C. After brief wash with PBST (phosphate buffer saline +0.1% Tween 20) and AP developing buffer (100 mM Tris-HCl, pH 9.5, 100 mM NaCl, 50 mM MgCl2), the embryos were developed with alkaline phosphatase substrate (0.34 mg/mL nitroblue tetrazolium, 0.18 mg/mL X-phosphate in 100 mM Tris pH 9.5, 100 mM NaCl, 50 mM MgCl2) and developed until desired signal was obtained. All embryos were observed and photographed as described in previous section.

3.5. Whole-Mount in Situ Hybridization

The procedures for whole-mount in situ hybridization was performed as previously described [33], except that vegfaa165 [34] were used as probes. Sequences encoding vegfaa165 isoform was amplified by PCR as previously described [34] and subsequently cloned into pGEM-T-easy vector. This plasmid was used to generate an antisense digoxigenin (DIG)-labeled riboprobe for in situ hybridization. Zebrafish embryos were fixed with 4% paraformaldehyde overnight and permeated by 100% methanol overnight at −20 °C. After that, embryos were rehydrated and digested with proteinase K. After a brief fixation by 4% paraformaldehyde, embryos were then prehybridized in hybridization buffer (50% formamide, 5 × SSC, 50 μg/mL yeast RNA, 25 μg/mL heparin) at 68 °C for at least 2 h and hybridized with DIG-labeled riboprobe overnight at 68 °C. Unbound and excessive probe was removed by washes in 2 × SSC followed by two washes in 0.2 × SSC for 30 min at 68 °C. After three rinses with PBST, embryos were blocked in 5% sheep serum (in PBST) for 1 h at room temperature and then incubated with sheep-anti-DIG-alkaline phosphatase (1:2000; Roche) for at least 2 h at room temperature. Unbound and excess antibody was removed by washing eight times in PBST for 2 h with gentle shaking. After three washes with AP developing buffer, the embryos were developed with AP substrate until desired signal was obtained. The
reaction was stopped by washing in PBST for several times. The stained embryos were observed under
a stereomicroscope or microscope equipped with DIC.

4. Conclusions

We have synthesized and identified several chalcone-based derivatives as a series of novel pro-angiogenic
compounds using zebrafish in vivo model. Concomitant to the induction of angiogenesis, upregulated
expression of *vegfa*, a key factor for angiogenesis, was observed. Further optimization of these chalcone
derivatives may produce more potent pro-angiogenic agents for angiotherapy.

Acknowledgments

This study was supported by the Ministry of Science and Technology, China, under grant number of
NSC 101-2313-B-032-001-MY3.

Author Contributions

Chao-Yuan Chang, Chiung-Fang Chang and Ya-Ting Lee carried out the experiments and analyzed
the data. Po-Chih Chen did the chemicals synthesis. Ching-Yuh Chern and Yau-Hung Chen gave
discussion and helped in editing the manuscript. Yau-Hung Chen, Ching-Yuh Chern and Jen-Ning Tsai
were principal investigators of this project and Jen-Ning Tsai drafted this manuscript.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Go, M.L.; Wu, X.; Liu, X.L. Chalcones: An update on cytotoxic and chemoprotective properties. *Curr. Med. Chem.* **2005**, *12*, 481–499.
2. Ajaiyeoba, E.O.; Ogbole, O.O.; Abiodun, O.O.; Ashidi, J.S.; Houghton, P.J.; Wright, C.W. Cajachalcone: An antimalarial compound from *Cajanus cajan* leaf extract. *J. Parasitol. Res.* **2013**, *2013*, doi:10.1155/2013/703781.
3. Ajiboye, T.O.; Yakubu, M.T.; Oladiji, A.T. Electrophilic and reactive oxygen species detoxification potentials of chalcone dimers is mediated by redox transcription factor Nrf-2. *J. Biochem. Mol. Toxicol.* **2014**, *28*, 11–22.
4. Chen, Y.H.; Wang, W.H.; Wang, Y.H.; Lin, Z.Y.; Wen, C.C.; Chern, C.Y. Evaluation of the anti-inflammatory effect of chalcone and chalcone analogues in a zebrafish model. *Molecules* **2013**, *18*, 2052–2060.
5. Fang, X.; Yang, B.; Cheng, Z.; Yang, M.; Su, N.; Zhou, L.; Zhou, J. Synthesis and antitumor activity of novel nitrogen mustard-linked chalcones. *Arch. Pharm.* **2013**, *346*, 292–299.
6. Wu, J.; Li, J.; Cai, Y.; Pan, Y.; Ye, F.; Zhang, Y.; Zhao, Y.; Yang, S.; Li, X.; Liang, G. Evaluation and discovery of novel synthetic chalcone derivatives as anti-inflammatory agents. *J. Med. Chem.* **2011**, *54*, 8110–8123.
7. Avila, H.P.; Smania Ede, F.; Monache, F.D.; Smania, A., Jr. Structure-activity relationship of antibacterial chalcones. *Bioorg. Med. Chem.* **2008**, *16*, 9790–9794.

8. Mojzis, J.; Varinska, L.; Mojzisova, G.; Kostova, I.; Mirossay, L. Antiangiogenic effects of flavonoids and chalcones. *Pharmacol. Res. Off. J. Ital. Pharmacol. Soc.* **2008**, *57*, 259–265.

9. Folkman, J.; Shing, Y. Angiogenesis. *J. Biol. Chem.* **1992**, *267*, 10931–10934.

10. Persson, A.B.; Buschmann, I.R. Vascular growth in health and disease. *Front. Mol. Neurosci.* **2011**, *4*, 14, doi:10.3389/fnmol.2011.00014.

11. Carmeliet, P.; Jain, R.K. Angiogenesis in cancer and other diseases. *Nature* **2000**, *407*, 249–257.

12. Holmes, D.I.; Zachary, I. The vascular endothelial growth factor (VEGF) family: Angiogenic factors in health and disease. *Genome Biol.* **2005**, *6*, 209, doi:10.1186/gb-2005-6-2-209.

13. Cross, M.J.; Dixelius, J.; Matsumoto, T.; Claesson-Welsh, L. VEGF-receptor signal transduction. *Trends Biochem. Sci.* **2003**, *28*, 488–494.

14. Staton, C.A.; Reed, M.W.; Brown, N.J. A critical analysis of current *in vitro* and *in vivo* angiogenesis assays. *Int. J. Exp. Pathol.* **2009**, *90*, 195–221.

15. Lieschke, G.J.; Currie, P.D. Animal models of human disease: Zebrafish swim into view. *Nat. Rev. Genet.* **2007**, *8*, 353–367.

16. Gore, A.V.; Monzo, K.; Cha, Y.R.; Pan, W.; Weinstein, B.M. Vascular development in the zebrafish. *Cold Spring Harb. Perspect. Med.* **2012**, *2*, a006684.

17. Lawson, N.D.; Weinstein, B.M. *In vivo* imaging of embryonic vascular development using transgenic zebrafish. *Dev. Biol.* **2002**, *248*, 307–318.

18. Lee, Y.T.; Fong, T.H.; Chen, H.M.; Chang, C.Y.; Wang, Y.H.; Chern, C.Y.; Chen, Y.H. Toxicity assessments of chalcone and some synthetic chalcone analogues in a zebrafish model. *Molecules* **2014**, *19*, 641–650.

19. Ohkatsu, Y.; Satoh, T. Antioxidant and photo-antioxidant activities of chalcone derivatives. *J. Jpn. Pet. Inst.* **2008**, *51*, 298–308.

20. Karki, R.; Thapa, P.; Kang, M.J.; Jeong, T.C.; Nam, J.M.; Kim, H.L.; Na, Y.; Cho, W.J.; Kwon, Y.; Lee, E.S. Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl pyridines. *Bioorg. Med. Chem.* **2010**, *18*, 3066–3077.

21. Isogai, S.; Horiguchi, M.; Weinstein, B.M. The vascular anatomy of the developing zebrafish: An atlas of embryonic and early larval development. *Dev. Biol.* **2001**, *230*, 278–301.

22. Van Rooijen, E.; Voest, E.E.; Logister, I.; Bussmann, J.; Korving, J.; van Eeden, F.J.; Giles, R.H.; Schulte-Merker, S. von Hippel-Lindau tumor suppressor mutants faithfully model pathological hypoxia-driven angiogenesis and vascular retinopathies in zebrafish. *Dis. Models Mech.* **2010**, *3*, 343–353.

23. Nicoli, S.; de Sena, G.; Presta, M. Fibroblast growth factor 2-induced angiogenesis in zebrafish: The zebrafish yolk membrane (ZFYM) angiogenesis assay. *J. Cell. Mol. Med.* **2009**, *13*, 2061–2068.

24. Lee, Y.S.; Lim, S.S.; Shin, K.H.; Kim, Y.S.; Ohuchi, K.; Jung, S.H. Anti-angiogenic and anti-tumor activities of 2′-hydroxy-4′-methoxychalcone. *Biol. Pharm. Bull.* **2006**, *29*, 1028–1031.

25. Bahary, N.; Goishi, K.; Stuckenholz, C.; Weber, G.; Leblanc, J.; Schafer, C.A.; Berman, S.S.; Klagsbrun, M.; Zon, L.I. Duplicate VegfA genes and orthologues of the KDR receptor tyrosine kinase family mediate vascular development in the zebrafish. *Blood* **2007**, *110*, 3627–3636.
26. Nasevicius, A.; Larson, J.; Ekker, S.C. Distinct requirements for zebrafish angiogenesis revealed by a VEGF-A morphant. Yeast 2000, 17, 294–301.

27. Kawamura, H.; Li, X.; Goishi, K.; van Meeteren, L.A.; Jakobsson, L.; Cebe-Suarez, S.; Shimizu, A.; Edholm, D.; Ballmer-Hofer, K.; Kjellen, L.; et al. Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization. Blood 2008, 112, 3638–3649.

28. Zhu, X.F.; Xie, B.F.; Zhou, J.M.; Feng, G.K.; Liu, Z.C.; Wei, X.Y.; Zhang, F.X.; Liu, M.F.; Zeng, Y.X. Blockade of vascular endothelial growth factor receptor signal pathway and antitumor activity of ON-III (2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone), a component from Chinese herbal medicine. Mol. Pharm. 2005, 67, 1444–1450.

29. Nam, N.H.; Kim, Y.; You, Y.J.; Hong, D.H.; Kim, H.M.; Ahn, B.Z. Cytotoxic 2',5'-dihydroxychalcones with unexpected antiangiogenic activity. Eur. J. Med. Chem. 2003, 38, 179–187.

30. Westerfield, M. The zebrafish Book. A Guide for the Laboratory Use of Zebrafish (Danio rerio), 5th ed.; University of Oregon Press: Eugene, OR, USA, 2007.

31. Kimmel, C.B.; Ballard, W.W.; Kimmel, S.R.; Ullmann, B.; Schilling, T.F. Stages of embryonic development of the zebrafish. Dev. Dyn. 1995, 203, 253–310.

32. Childs, S.; Chen, J.N.; Garrity, D.M.; Fishman, M.C. Patterning of angiogenesis in the zebrafish embryo. Development 2002, 129, 973–982.

33. Chen, Y.H.; Lin, Y.T.; Lee, G.H. Novel and unexpected functions of zebrafish CCAAT box binding transcription factor (NF-Y) B subunit during cartilages development. Bone 2009, 44, 777–784.

34. Lawson, N.D.; Vogel, A.M.; Weinstein, B.M. Sonic hedgehog and vascular endothelial growth factor act upstream of the Notch pathway during arterial endothelial differentiation. Dev. Cell 2002, 3, 127–136.

Sample Availability: Samples of the compounds are available from the authors.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).